文献速递腹部技术与安全CT

转移性结直肠癌患者影像学淋巴结增大的预后价值:随机、开放标签FIRE-3/AIO KRK0306试验的子组分析

Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.
PubMed 文献 · Eur J Radiol · 2018-01-06

基于FIRE-3/AIO KRK0306随机试验的RAS野生型转移性结直肠癌患者(n=400),回顾性分析339例可评估基线CT,淋巴结增大(≥10 mm)患者中位总生存21.7个月 vs 无增大者33.2个月(HR=1.61,95%CI 1.23-2.09,P<0.001),多变量分析确认(HR=1.37,95%CI 1.02-1.83,P=0.036)。基线分期影像学淋巴结增大具有独立不良预后价值。

要点

  • 基线CT淋巴结增大(≥10 mm)与转移性结直肠癌患者总生存缩短独立相关(多变量HR=1.37)。
  • 淋巴结增大患者中位总生存21.7个月 vs 无增大者33.2个月,HR=1.61(95%CI 1.23-2.09,P<0.001)。
  • 无进展生存呈一致但未达统计学显著的趋势(9.9 vs 11.1个月;HR=1.23,95%CI 0.98-1.54,P=0.072)。

核心结论

  • 基线分期时影像学淋巴结增大在既有及潜在预后参数之外具有不良预后价值。

研究设计与样本

  • 前瞻性随机开放标签FIRE-3/AIO KRK0306试验的子组回顾性分析;RAS野生型转移性结直肠癌患者n=400,可评估基线CT n=339;一线氟尿嘧啶、亚叶酸钙和伊立替康联合西妥昔单抗或贝伐珠单抗;回顾性分析区域及远处增大淋巴结的预后相关性,采用单变量和多变量Cox比例风险回归。

诊断标准与关键数值

  • 影像学淋巴结增大定义为淋巴结≥10 mm。
  • 淋巴结增大患者中位总生存21.7个月 vs 无增大者33.2个月,HR=1.61(95%CI 1.23-2.09;P<0.001)。
  • 多变量分析确认总生存差异:HR=1.37(95%CI 1.02-1.83;P=0.036)。
  • 无进展生存:淋巴结增大者9.9个月 vs 无增大者11.1个月;HR=1.23(95%CI 0.98-1.54;P=0.072),未达统计学显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the prognostic impact of radiologically enlarged lymph nodes ≥ 10 mm on the survival of patients with metastatic colorectal cancer.

MATERIALS AND METHODS: The prospective, randomized, open-label FIRE-3/AIO KRK0306 trial evaluated the first-line therapy of patients with KRAS exon 2 wild-type metastatic colorectal cancer with fluorouracil, folinic acid and irinotecan plus either cetuximab or bevacizumab. In the RAS wild-type population (n = 400), adequately evaluable baseline computed tomographies (n = 339) were reviewed for enlarged regional and distant lymph nodes. Their prognostic relevance was retrospectively analyzed in uni- and multivariable Cox proportional hazard regressions.

RESULTS: Median overall survival was 21.7 months in patients with enlarged lymph nodes and 33.2 months in patients without (hazard rate ratio [HR] = 1.61, 95% confidence interval [CI], 1.23-2.09; P < 0.001). This was confirmed in multivariable analysis (HR = 1.37, 95% CI, 1.02-1.83; P = 0.036). Progression-free survival of patients with enlarged lymph nodes showed a consistent but insignificant trend (9.9 vs. 11.1 months; HR = 1.23, 95% CI, 0.98-1.54; P = 0.072). Enlarged lymph nodes were also associated with BRAF-mutations (P = 0.004).

CONCLUSION: The presence of radiologically enlarged lymph nodes in baseline staging has a negative prognostic value beyond established and potential prognostic parameters.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Hofmann FO, Holch JW, Heinemann V, et al. Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. Eur J Radiol. 2018. PMID: 29496069. doi:10.1016/j.ejrad.2018.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。